Real-world data on patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) remain scarce. In this descriptive observational retrospective cohort study, we describe characteristics, treatments, and real-world progression-free survival (rwPFS) and overall survival (OS) among patients with ROS1-positive advanced NSCLC (de novo or recurrent) using secondary data pooled from clinical sites in Canada, France, Germany, Portugal, and Spain as part of the Oncology Evidence Network. Site-specific patient inclusion periods occurred between 2009 and 2023, with follow-up to 2024, allowing
- Cheung, W. Y.
- Lee, A.
- Bote de Cabo, H.
- Burdenski, K.
- Christopoulos, P.
- Pinto-Correia, B.
- Deshayes, S.
- Girard, N.
- Hindocha, P.
- Madden, Á
- Mella, M.
- Moreira, J.
- Rizzi, S.
- Abreu, D. R.
- Soares, M.
- Thomas, J.
- Han, M.
- Calvet, C. Y.
- Emanuel, G.
- Glassberg, M. B.
- Jacobs, H.
- Rault, C.
- Yuan, Y.
- Chouaid, C.
Keywords
- Humans
- *Carcinoma, Non-Small-Cell Lung/drug therapy/mortality/genetics/pathology
- *Lung Neoplasms/drug therapy/mortality/genetics/pathology
- Male
- Female
- Aged
- Middle Aged
- Retrospective Studies
- *Protein-Tyrosine Kinases/genetics/metabolism
- Canada
- Europe
- *Proto-Oncogene Proteins/genetics/metabolism
- Adult
- Aged, 80 and over
- Ros1
- locally advanced
- metastatic
- non-small cell lung cancer
- real world
- survival
- treatment patterns
